In the News

MARKETS INSIDER

September 12, 2017

Follow
Harbour BioMed
on WeChat

Back to list

MARKETS INSIDER

September 12, 2017

SEOUL, South Korea and SHANGHAI and CAMBRIDGE, Massachusetts, Sept. 12, 2017 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (009420.KS) and Harbour BioMed announced today that they have entered into a strategic collaboration and license agreement to develop, manufacture and commercialize in Greater China (including Hong Kong, Macau and Taiwan) HanAll's two novel biologics, the anti-FcRn monoclonal antibody, HL161, for the treatment of pathogenic IgG-mediated autoimmune diseases, and the anti-TNF ophthalmic solution, HL036, for dry eye and other inflammatory diseases.  

Media Contact:

Harbour BioMed Public Relations

E-mail: pr@harbourbiomed.com